Company intelligence / Profile preview

AuraGen

Menlo Park, California, United States

Ownership: Private
Development stage: Other

Overview

AuraGen was a medical technology company focused on developing advanced solutions for autologous fat grafting and soft tissue augmentation. The company's flagship product, the AuraGen system, was a proprietary closed-loop device designed to harvest, process, and deliver high-viability fat tissue for plastic and reconstructive procedures. By standardizing the fat transfer process, the technology aimed to improve the predictability and long-term outcomes of tissue grafting. In May 2018, AuraGen was acquired by Sientra, a medical aesthetics company, to enhance its portfolio of breast and body contouring products.

Therapeutic areas: OtherWomen's HealthDermatology
Modalities: DeviceCell therapy
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on AuraGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AuraGen.

Explore the full profile